2·d),觀察組為10 mg/(m2·d)。比較兩組治療3個月后的療效和不良反應(yīng)發(fā)生情況以及治療前后的IL-13、IL-18和IL-32水平。結(jié)果 兩組的治療總有效率分別為80.00%和76.67%,差異無統(tǒng)計(jì)學(xué)意義;兩組的不良反應(yīng)發(fā)生情況差異不具有統(tǒng)計(jì)學(xué)意義,但觀察組的不良反應(yīng)總發(fā)生率低于對照組。治療前,兩組的IL-13、IL-18和IL-32水平差異無統(tǒng)計(jì)學(xué)意義;兩組治療后的IL-13水平高于且IL-18和IL-32水平低于治療前,同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05);治療后,觀察組的IL-13水平高于對照組,且IL-18和IL-32水平低于對照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 地西他濱對MDS的療效明顯,劑量為10 mg/(m2·d)時(shí)臨床效果好,不良反應(yīng)少,可更有效改善免疫功能,并且更經(jīng)濟(jì)。;Objective To discuss the influence of small-dose decitabine on curative effect, interleukin-13 (IL-13), interleukin-18 (IL-18) and interleukin-32 (IL-32) levels of myelodysplastic syndrome (MDS) patients.Methods A total of 60MDS patientstreated in our hospital from January 2015 to January 2017 were studied and were divided into control group (30 cases) and observation group (30 cases) according to the time of admission. All patients were treated with decitabine, control group was given by 25 mg/(m2·d) and observation group was given by 10 mg/(m2·d). The curative effect, IL-13, IL-18 and IL-32 levels of two groups before and after 3 months treatment were compared.Results The difference in total effective rate of two groups was not statistically significant. The difference in adverse reactions between two groups was not statistically significant, but the total incidence of adverse reactions of observation group was lower than that of control group. Before treatment, IL-13, IL-18 and IL-32 levels of two groups had no statistical difference. IL-18 and IL-32 levels of two groups after treatment were lower and IL-13 was higher than those before treatment (P< 0.05).Conclusion The curative effect of decitabine on MDS is obvious. The curative effect of 10 mg/(m2·d) is good. Its adverse reaction is little and more economical, can improve the immune function more effectively."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2018年第41卷第2期 >2018,41(2):283-286. DOI:10.7501/j.issn.1674-6376.2018.02.023
上一篇 | 下一篇

小劑量地西他濱對骨髓增生異常綜合征患者的療效及對IL-13、IL-18和IL-32的影響

Influence of small-dose decitabine on curative effect, IL-13, IL-18 and IL-32 of MDS patients

發(fā)布日期:2018-03-17
您是第位訪問者
藥物評價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031